IP Library › Granted Patent US 10,744,179
Granted Patent B2
US 10,744,179 · App. 15/512,139 · Granted Aug 18, 2020

Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing

Inventors: Seamus J. Martin (Dublin, IE); Conor Henry (Dublin, IE); Graeme Sullivan (Dublin, IE)
Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY
A61K38/07A61K31/10A61K31/137A61K31/19A61K31/222A61K31/277A61K31/495A61K31/496A61K31/675A61K31/713A61K38/005A61K38/05A61K38/06A61K38/55A61K39/3955C07K16/244C07K16/245C07K16/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,744,179
App. No.
15/512,139
Granted
Aug 18, 2020
Kind
B2
Abstract

This invention relates to the use of an agent capable of inhibiting IL-36 proteolytic processing for the treatment and/or reduction of inflammation in a subject. Advantageously, the agent prevents the production of a biologically active IL-36 to prevent and/or reduce the pro-inflammatory effects of IL-36. The invention also relates to a method for treatment and/or reduction of inflammation and compositions for treating and/or reducing inflammation.

Claims (67)

1. A method for the treatment of at least one inflammatory skin disorder selected from the group consisting of plaque psoriasis, guttate psoriasis, palmoplantar psoriasis, generalized pustular psoriasis, flexural psoriasis, inverse psoriasis, erythrodermic psoriasis, psoriasis vulgaris, and arthritic psoriasis, in a subject in need thereof, the method comprising:

administering to the subject an effective amount of at least one peptide, or a combination thereof, selected from the group consisting of:

a) a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:1, wherein the 3 to 8 consecutive amino acids comprises:

Asp-Pro-Gln-Arg (NPQR);

Pro-Gln-Arg (PQR);

Gln-Arg-Glu-Ala (QREA);

Asp-Pro-Gln-Arg (NPQR-CMK);

Pro-Gln-Arg (PQR-CMK);

or

Gln-Arg-Glu-Ala (QREA-CMK);

b) a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:2, wherein the 3 to 8 consecutive amino acids comprises:

Arg-Ala-Val (RAV);

Gly-Arg-Ala-Val (GRAV);

Ala-Val-Tyr-Gln (AVYQ);

Arg-Ala-Val (RAV-CMK);

Gly-Arg-Ala-Val (GRAV-CMK);

or

Ala-Val-Tyr-Gln (AVYQ-CMK);

c) a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:28, wherein the 3 to 8 consecutive amino acids comprises:

Lys-Ala-Leu (KAL);

or

Lys-Ala-Leu (KAL-CMK);

and

d) a peptide selected from the group consisting of:

Ala-Leu-Ala (ALA);

Met-Ala-Leu-Ala (MALA);

Ala-Leu-Ala (ALA-CMK);

and

Met-Ala-Leu-Ala (MALA-CMK).

2. The method of claim 1 , wherein the peptide is:

a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:1, or a combination thereof, wherein the 3 to 8 consecutive amino acids comprises:

Asp-Pro-Gln-Arg (NPQR);

Pro-Gln-Arg (PQR);

Gln-Arg-Glu-Ala (QREA);

Asp-Pro-Gln-Arg (NPQR-CMK);

Pro-Gln-Arg (PQR-CMK);

or

Gln-Arg-Glu-Ala (QREA-CMK).

3. The method of claim 1 , wherein the peptide is:

a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:2, or a combination thereof, wherein the 3 to 8 consecutive amino acids comprises:

Arg-Ala-Val (RAV-CMK);

Gly-Arg-Ala-Val (GRAV-CMK);

Ala-Val-Tyr-Gln (AVYQ-CMK);

Arg-Ala-Val (RAV);

Gly-Arg-Ala-Val (GRAV);

or

Ala-Val-Tyr-Gln (AVYQ).

4. The method of claim 1 , wherein the peptide is:

a peptide consisting of 3 to 8 consecutive amino acids of SEQ ID NO:28, or a combination thereof, wherein the 3 to 8 consecutive amino acids comprises:

Lys-Ala-Leu (KAL);

or

Lys-Ala-Leu (KAL-CMK).

5. The method of claim 1 , wherein the peptide is:

a peptide, or a combination thereof, selected from the group consisting of:

Ala-Leu-Ala (ALA);

Met-Ala-Leu-Ala (MALA);

Ala-Leu-Ala (ALA-CMK);

Met-Ala-Leu-Ala (MALA-CMK).

6. The method of claim 1 , wherein the at least one inflammatory skin disorder is plaque psoriasis or psoriasis vulgaris.

7. The method of claim 1 , wherein the at least one inflammatory skin disorder is guttate psoriasis.

8. The method of claim 1 , wherein the at least one inflammatory skin disorder is palmoplantar psoriasis.

9. The method of claim 1 , wherein the at least one inflammatory skin disorder is generalized pustular psoriasis.

10. The method of claim 1 , wherein the at least one inflammatory skin disorder is flexural psoriasis.

11. The method of claim 1 , wherein the at least one inflammatory skin disorder is inverse psoriasis.

12. The method of claim 1 , wherein the at least one inflammatory skin disorder is erythrodermic psoriasis.

13. The method of claim 1 , wherein the at least one inflammatory skin disorder is arthritic psoriasis.

14. The method of claim 1 , wherein the administration is selected from the group consisting of topical, oral, parenteral, or intravenous.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2017
From: MARTIN, SEAMUS J.; HENRY, CONOR; SULLIVAN, GRAEME
To: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF THE BOARD, OF THE COLLEGE OF THE HOLY & UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Reel/Frame 042362/0384 →
Priority Claims (1)
EP 14185397 · Sep 18, 2014 · regional
Continuity (1)
Related Publication 20170281716A1 · Oct 5, 2017